Company Description
Tempus AI, Inc. operates as a healthcare technology company.
It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.
In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data.
The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023.
Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 14, 2024 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 2,400 |
| CEO | Eric Lefkofsky |
Contact Details
Address: 600 West Chicago Avenue, Suite 510 Chicago, Illinois 60654 United States | |
| Phone | 800 976 5448 |
| Website | tempus.com |
Stock Details
| Ticker Symbol | TEM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $37.00 |
| CIK Code | 0001717115 |
| CUSIP Number | 71535D106 |
| ISIN Number | US88023B1035 |
| Employer ID | 47-4903308 |
| SIC Code | 7370 |
Key Executives
| Name | Position |
|---|---|
| Eric P. Lefkofsky | Co-Founder, Chief Executive Officer, President and Chairman |
| Ryan Fukushima | Chief Operating Officer |
| Andrew Polovin | Executive Vice President, General Counsel and Secretary |
| James Rogers | Chief Financial Officer |
| Ryan M. Bartolucci CPA | Chief Accounting Officer |
| Shane Colley | Chief Technology Officer |
| Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer |
| Erik Phelps | Executive Vice President, Assistant Secretary and Chief Administrative and Legal Officer |
| Elizabeth Krutoholow | Vice President of Investor Relations and Competitive Intelligence |
| Patty Spiller | Senior Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2025 | ARS | Filing |
| Apr 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 7, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 144 | Filing |
| Mar 28, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 21, 2025 | 144 | Filing |
| Mar 18, 2025 | 144 | Filing |
| Mar 18, 2025 | 144 | Filing |
| Mar 17, 2025 | 144 | Filing |
| Mar 17, 2025 | 144 | Filing |